His primary areas of investigation include Genetics, Neurofibromatosis, Locus, Gene and Exon. His Genetics study is mostly concerned with Neurofibromin 1, Complementary DNA, Open reading frame, Nucleic acid sequence and Amino acid. His Neurofibromatosis study integrates concerns from other disciplines, such as Cancer research, Internal medicine and Endocrinology.
His Locus study combines topics in areas such as Camptodactyly, Knockout mouse, Hearing loss, Tall Stature and Bone growth. His work on genomic DNA, Intron and Chromosomal translocation as part of his general Gene study is frequently connected to Diamond–Blackfan anemia, thereby bridging the divide between different branches of science. The Exon study combines topics in areas such as Genetic heterogeneity, Point mutation and Null allele.
His main research concerns Neurofibromatosis, Genetics, Internal medicine, Pathology and Gene. His Neurofibromatosis research is multidisciplinary, relying on both Dysplasia and Pseudarthrosis. His research is interdisciplinary, bridging the disciplines of Molecular biology and Genetics.
His Molecular biology research is multidisciplinary, incorporating elements of Complementary DNA and Chromosome 17. His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Oncology. David Viskochil combines subjects such as genomic DNA, Gene mapping and Loss of heterozygosity with his study of Locus.
David Viskochil spends much of his time researching Neurofibromatosis, Genetics, Internal medicine, Pediatrics and Clinical trial. His Neurofibromatosis study is focused on Pathology in general. David Viskochil connects Genetics with Terminal in his study.
In the field of Internal medicine, his study on Disease overlaps with subjects such as Clinical diagnosis. His Pediatrics research is multidisciplinary, incorporating perspectives in Normal range and Proband. His research integrates issues of Medical therapy, Surgery, MEK inhibitor and Patient participation in his study of Clinical trial.
His primary areas of study are Neurofibromatosis, Internal medicine, Clinical trial, Oncology and Malignant peripheral nerve sheath tumor. David Viskochil conducted interdisciplinary study in his works that combined Neurofibromatosis and Early childhood. His studies deal with areas such as Tolerability and Mutation as well as Internal medicine.
His work in Clinical trial addresses issues such as Surgery, which are connected to fields such as Placebo and Cohort study. His Oncology research integrates issues from Phenotype, PI3K/AKT/mTOR pathway, Peripheral Nerve Sheath Tumors and Tuberous sclerosis. His Malignant peripheral nerve sheath tumor research incorporates themes from Clinical endpoint, Everolimus, Combination therapy and Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.
David H. Gutmann;Arthur Aylsworth;John C. Carey;Bruce Korf.
A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations.
Richard M. Cawthon;Robert Weiss;Gangfeng Xu;David Viskochil.
The neurofibromatosis type 1 gene encodes a protein related to GAP
Gangfeng Xu;Peter O'Connell;David Viskochil;Richard Cawthon.
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.
David Viskochil;Arthur M. Buchberg;Gangfeng Xu;Richard M. Cawthon.
Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome
Ute Schell;Andreas Hehr;George J. Feldman;Nathaniel H. Robin.
Human Molecular Genetics (1995)
Genomic organization of the neurofibromatosis 1 gene (NF1).
Ying Li;Peter O'connell;Heidi Huntsman Breidenbach;Richard Cawthon.
The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I.
Gregory M. Pastores;Pamela Arn;Michael Beck;Joe T R Clarke.
Molecular Genetics and Metabolism (2007)
Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1
Rui M. Costa;Tao Yang;Duong P. Huynh;Stefan M. Pulst.
Nature Genetics (2001)
Identification of NF1 mutations in both alleles of a dermal neurofibroma
Shun'ichi Sawada;Scott Florell;Smita M. Purandare;Mayumi Ota.
Nature Genetics (1996)
Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.
Markku M. Miettinen;Cristina R. Antonescu;Christopher D.M. Fletcher;Aerang Kim.
Human Pathology (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: